Kim and collaborators have reported that cancer-derived exosomes loaded CRISPR/Cas9 could restrain the expression of poly(ADP-ribose) polymerase-1 (PARP-1) to enhance the chemosensitivity of cisplatin and achieve satisfactory therapeutic effects in ovarian cancer tumors [75]. This evidence concerns the gene PARP1 and ovarian carcinoma.